Longitudinal modeling of age-related memory decline and the APOE ε4 effect

New England Journal of Medicine

Volumn 361, Issue 3, 2009, Pages 255-263

  Caselli, Richard J ^a   Dueck, Amylou C ^a   Osborne, David ^a   Sabbagh, Marwan N ^b   Connor, Donald J ^b   Ahern, Geoffrey L ^c   Baxter, Leslie C ^d   Rapcsak, Steven Z ^c   Shi, Jiong ^d   Woodruff, Bryan K ^a   Locke, Dona E C ^a   Snyder, Charlene Hoffman ^a   Alexander, Gene E ^c   Rademakers, Rosa ^f   Reiman, Eric M ^c,e  

^a MAYO CLINIC   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

^e TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGE; AGED; ALLELE; ARTICLE; AWARENESS; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DEPTH PERCEPTION; EDUCATION; FEMALE; FOLLOW UP; HEALTH STATUS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LONGITUDINAL STUDY; MALE; MEMORY DISORDER; MENTAL HEALTH; MODEL; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL;

EID: 67650899270     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0809437     Document Type: Article

References (40)

1. West RL. An application of prefrontal cortex function theory to cognitive aging. Psychol Bull 1996;120:272-92.
2. Verhaeghen P, Cerella J. Aging, executive control, and attention: a review of metaanalyses. Neurosci Biobehav Rev 2002;26:849-57.
3. Treitz FH, Heyder K, Daum I. Differential course of executive control changes during normal aging. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2007;14:370-93.
4. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303-8. [Erratum, Arch Neurol 1999;56:760.]
5. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early stage Alzheimer disease. Arch Neurol 2001;58:397-405.
6. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review) - report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-42.
7. Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA. Mild cognitive impairment: risk of Alzheimer's disease and rate of cognitive decline. Neurology 2006;67:441-5.
8. Albert M, Blacker D, Moss MB, Tanzi R, McArdle JJ. Longitudinal change in cognitive performance among individuals with mild cognitive impairment. Neuropsychology 2007;21:158-69.
9. Howieson DB, Carlson NE, Moore MM, et al. Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc 2008;14:192-8.
10. Salthouse TA. Memory aging from 18 to 80. Alzheimer Dis Assoc Disord 2003;17:162-7.
11. Burke DM, Mackay DG. Memory, language, and ageing. Philos Trans R Soc Lond B Biol Sci 1997;352:1845-56.
12. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
13. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
14. Baxter LC, Caselli RJ, Johnson SC, Reiman E, Osborne D. Apolipoprotein E epsilon 4 affects new learning in cognitively normal individuals at risk for Alzheimer's disease. Neurobiol Aging 2003;24:947-52.
15. Caselli RJ, Reiman EM, Osborne D, et al. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology 2004;62:1990-5.
16. Caselli RJ, Reiman EM, Locke DE, et al. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol 2007;64:1306-11.
17. Caselli RJ, Chen K, Lee W, Alexander GE, Reiman EM. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch Neurol 2008;65:1231-6.
18. Small SA. Age-related memory decline: current concepts and future directions. Arch Neurol 2001;58:360-4.
19. Petersen RC, Smith G, Kokmen E, Ivnik RJ, Tangalos EG. Memory function in normal aging. Neurology 1992;42:396-401.
20. Small SA, Stern Y, Tang M, Mayeux R. Selective decline in memory function among healthy elderly. Neurology 1999;52:1392-6.
21. Ferris SH, Aisen PS, Cummings J, et al. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord 2006;20:Suppl 3:S109-S123.
22. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res 1990;31:545-8.
23. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and education level. JAMA 1993;269:2386-91.
24. Lezak MD, Howieson DB, Loring DW. Neuropsychological assessment. 4th ed. New York: Oxford University Press, 2004.
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed., rev.: DSM-III-R. Washington DC: American Psychiatric Association, 1987.
26. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, DC: American Psychiatric Association, 1994.
28. Steinberg BA, Bieliauskas LA, Smith GE, Ivnik RJ, Malec JF. Mayo's Older Americans Normative Studies: age- and IQ-adjusted norms for the Auditory Verbal Learning Test and the Visual Spatial Learning Test. Clin Neuropsychol 2005;19:464-523.
29. Rey A. L'examen clinique en psychologie. Paris: Presses Universitaires de France, 1964.
30. Ware JH, Dockery DW, Louis TA, XU XP, Ferris BG Jr, Speizer FE. Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. Am J Epidemiol 1990;132:685-700.
31. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. Hoboken, NJ: John Wiley, 2004.
32. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009;106:6820-5.
33. Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a oneyear autopsy population from a geriatric hospital. Cereb Cortex 1994;4:138-50.
34. Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp Neurol 1998;153:152-5.
35. Morishima-Kawashima M, Oshima N, Ogata H, et al. Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol 2000;157:2093-9.
36. Crystal HA, Dickson D, Sliwinski M, Masur D, Blau A, Lipton RB. Associations of status and change measures of neuropsychological function with pathologic changes in elderly, originally nondemented subjects. Arch Neurol 1996;53:82-7.
37. Alafuzoff I, Helisalmi S, Mannermaa A, Soininen H. Severity of cardiovascular disease, apolipoprotein E genotype, and brain pathology in aging and dementia. Ann N Y Acad Sci 2000;903:244-51.
38. Snowdon DA. Healthy aging and dementia: findings from the Nun Study. Ann Intern Med 2003;139:450-4.
39. Brickell KL, Steinbart EJ, Rumbaugh M, et al. Early-onset Alzheimer disease families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease. Arch Neurol 2006;63:1307-11.
40. Caselli RJ, Hentz JG, Osborne D, et al. Apolipoprotein E and intellectual achievement. J Am Geriatr Soc 2002;50:49-54.